Immunovia

The selection highlights the study's exceptional scientific and clinical significance and places it among the most impactful research presented at the world's largest conference in gastroenterology.

"This recognition reinforces the strength of our clinical validation study and the opportunity our test represents in addressing a critical unmet need," said Dr. Norma Palma, Vice President of Clinical and Medical Affairs at Immunovia and co-author of the study.

Dr. Aimee Lee Lucas, Chief of Gastroenterology and Hepatology at Mount Sinai West and Mount Sinai Morningside Hospitals and a member of Immunovia's Scientific Advisory Board, presented the study findings. The CLARITI study demonstrated strong performance of Immunovia's novel blood-based biomarker test for early detection of pancreatic cancer in a high-risk population.

Digestive Disease Week brings together more than 13,000 global attendees, including clinicians, researchers, and decision-makers. Recognition in both the plenary and Best of DDW sessions underscores Immunovia's growing leadership in early cancer detection and the potential impact of its technology in clinical practice.